OrganiGram Holdings Inc.

TSX:OGI.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.96 -1.43%

-$0.02 today

Market cap
$135.37M
Beta
1.84
P/E (TTM)
-7.2
EPS (TTM)
-$0.19
52W Low $1.37High $3.09

Volume 0.54M

Average 0.19M

OGI.TO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

OrganiGram Holdings Inc.TSX: OGI.TO

Financing Cash Flow · Q2 FY2026 · quarter ended Mar 2026

Financing cash flow turns negative

Q2 FY2026 financing cash flow was -CA$451K, compared with CA$40.66M a year earlier. Trailing-twelve-month financing cash flow was -CA$2.03M.

Context

  • Financing cash flow amounted to 15.2% of revenue in FY2025, down 52.3 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly financing cash flow holds near -CA$451K or moves back toward the trailing-twelve-month quarterly average of -CA$506.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$451K+0.2% QoQ
Last fiscal yearSep 2025
CA$39.33M-63.5% YoY
LTMMar 2026
-CA$2.03M-101.9% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-101.1%——
1 year-63.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

CAD · from the cash flow

Latest · FY2025
39.33M CAD
Year-over-year change
-63.5%
4-year CAGR
-31.1%

Financing Cash Flow vs competitors

How OGI.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -101.9% is the 9th highest of 10, against a peer median of -1.0%.
  • Financing cash flow amounts to 0.7% of revenue for OGI.TO, versus a peer median of 32.0%.
OGI.TO Competitors
Financing Cash Flow for OGI.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$399.12M CAD+168.5%—128.4%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$122.16M USD+399.3%+78.9%—
DR.TOMedical Facilities CorporationLTM Mar 2026$67.77M USD-43.9%+11.5%22.2%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$45.54M USD-215.7%+178.1%89.4%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$25.62M USD+311.3%+6.4%50.1%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$23.36M USD-1.0%+44.1%41.9%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$9.76M CAD+1148.2%—3.1%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$6.97M CAD-57.6%—4.4%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$2.03M CAD-101.9%—0.7%
TSND.TOTerrAscend Corp.LTM Mar 2026$601.11K USD-96.6%+4.6%0.2%
Peer median (excluding OGI.TO) —-1.0%+27.8%32.0%

Competitors are the stored peer set for OGI.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(130.7M)(14.28M)(229.48M)(45.44M)(24.76M)
Depreciation & Amortization31.03M24.91M24.17M12.08M17.98M
Deferred Income Tax42.21M(88K)(3.62M)0(13.77M)
Stock-Based Compensation3.9M5.13M5.29M7.18M4.22M
Change in Working Capital24.2M(22.88M)12.51M14.96M(2.12M)
Accounts Receivables(6.01M)(24.02M)12.51M(12.06M)(15.29M)
Inventory28.68M(12.22M)000
Accounts Payables2.06M12.15M000
Other Working Capital(542K)1.21M(5.52M)27.02M13.16M
Other Non-Cash Items776K(29M)155.33M15.09M12.47M
Operating Cash Flow(28.59M)(36.21M)(35.8M)3.87M(7.59M)
Capital Expenditures(12.33M)(48.78M)(26.9M)(5.34M)(17.05M)
Acquisitions (Net)(2.54M)(11.06M)1.03M257K(65.62M)
Purchases of Investments(120.02M)(15M)(10M)(29.24M)(1.01M)
Sales of Investments50.85M114.59M49.4M3.52M2.5M
Other Investing Activities(31.08M)4.29M(8.65M)(7.97M)(1.52M)
Investing Cash Flow(115.11M)44.03M1.36M(38.77M)(82.67M)
Debt Repayment(116.4M)(1.01M)(87K)(786K)(60K)
Common Stock Issued284.88M6.34M20K108.56M41.18M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.99M6.34M(750K)6K(1.79M)
Financing Cash Flow174.46M5.33M(817K)107.78M39.33M
Effect of Forex Changes0000313K
Net Change in Cash30.77M13.15M(34.65M)72.88M(49.01M)
Free Cash Flow(40.92M)(84.99M)(62.7M)(1.47M)(24.64M)

OrganiGram Holdings Inc.

TSX:OGI.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.